191 related articles for article (PubMed ID: 28364788)
1. The clinical research of Thinprep Cytology Test (TCT) combined with HPV-DNA detection in screening cervical cancer.
Liu Y; Zhang L; Zhao G; Che L; Zhang H; Fang J
Cell Mol Biol (Noisy-le-grand); 2017 Feb; 63(2):92-95. PubMed ID: 28364788
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of combined detection of thinprep cytology test and high risk human papillomavirus hybrid capture 2 assay in the screening and recurrence predication of cervical intraepithelial neoplasia].
Xu XY; Zhao W; Li GJ; Jin XY; Li YZ
Zhonghua Yi Xue Za Zhi; 2012 Sep; 92(35):2503-5. PubMed ID: 23158720
[TBL] [Abstract][Full Text] [Related]
3. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
[TBL] [Abstract][Full Text] [Related]
4. ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients.
Husaiyin S; Jiao Z; Yimamu K; Maisaidi R; Han L; Niyazi M
PLoS One; 2021; 16(12):e0260915. PubMed ID: 34855928
[TBL] [Abstract][Full Text] [Related]
5. Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?
Gao K; Eurasian M; Zhang J; Wei Y; Zheng Q; Ye H; Li L
Gynecol Obstet Invest; 2015; 80(3):153-63. PubMed ID: 25832290
[TBL] [Abstract][Full Text] [Related]
6. Application of human papillomavirus in screening for cervical cancer and precancerous lesions.
Wang JL; Yang YZ; Dong WW; Sun J; Tao HT; Li RX; Hu Y
Asian Pac J Cancer Prev; 2013; 14(5):2979-82. PubMed ID: 23803065
[TBL] [Abstract][Full Text] [Related]
7. Primary HPV testing with cytology versus cytology alone in cervical screening-A prospective randomized controlled trial with two rounds of screening in a Chinese population.
Chan KKL; Liu SS; Wei N; Ngu SF; Chu MMY; Tse KY; Lau LSK; Cheung ANY; Ngan HYS
Int J Cancer; 2020 Aug; 147(4):1152-1162. PubMed ID: 31922265
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of variable methods for HPV testing].
Cheng JY; Bian ML; Ma L; Cong X; Chen Y; Liu J
Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):589-94. PubMed ID: 24199924
[TBL] [Abstract][Full Text] [Related]
9. [Combining high-risk human papillomavirus DNA test and cytological test to detect early cervical dysplasia].
Qian DY; Cen JM; Wang D; Zeng RH; Lin AH; Shu YH; Hong DH; Huang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Jan; 41(1):34-7. PubMed ID: 16635326
[TBL] [Abstract][Full Text] [Related]
10. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
[No Abstract] [Full Text] [Related]
12. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
[TBL] [Abstract][Full Text] [Related]
13. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
14. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.
Sun P; Song Y; Ruan G; Mao X; Kang Y; Dong B; Lin F
J Gynecol Oncol; 2017 Sep; 28(5):e50. PubMed ID: 28657218
[TBL] [Abstract][Full Text] [Related]
16. The clinical value of HPV E6/E7 and STAT3 mRNA detection in cervical cancer screening.
Fan Y; Shen Z
Pathol Res Pract; 2018 May; 214(5):767-775. PubMed ID: 29655523
[TBL] [Abstract][Full Text] [Related]
17. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
18. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
[No Abstract] [Full Text] [Related]
19. Distribution of HPV genotypes in Shanghai women.
Singh S; Zhou Q; Yu Y; Xu X; Huang X; Zhao J; Han L; Wang K; Sun J; Li F
Int J Clin Exp Pathol; 2015; 8(9):11901-8. PubMed ID: 26617946
[TBL] [Abstract][Full Text] [Related]
20. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
